Comparability of Insulin Binding to Erythrocytes and Monocytes from Hemodialysis Patients and Healthy Subjects

1981 ◽  
Vol 1 (1) ◽  
pp. 41-44 ◽  
Author(s):  
William A. Briggs ◽  
Kenneth S. Wielechowski ◽  
Sudesh K. Mahajan ◽  
Franklin D. McDonald
Author(s):  
Magda Wiśniewska ◽  
Natalia Serwin ◽  
Violetta Dziedziejko ◽  
Małgorzata Marchelek-Myśliwiec ◽  
Barbara Dołęgowska ◽  
...  

Background/Aims: Renalase is an enzyme with monoamine oxidase activity that metabolizes catecholamines; therefore, it has a significant influence on arterial blood pressure regulation and the development of cardiovascular diseases. Renalase is mainly produced in the kidneys. Nephrectomy and hemodialysis (HD) may alter the production and metabolism of renalase. The aim of this study was to examine the effect of bilateral nephrectomy on renalase levels in the serum and erythrocytes of hemodialysis patients. Methods: This study included 27 hemodialysis patients post-bilateral nephrectomy, 46 hemodialysis patients without nephrectomy but with chronic kidney disease and anuria and 30 healthy subjects with normal kidney function. Renalase levels in the serum and erythrocytes were measured using an ELISA kit. Results: Serum concentrations of renalase were significantly higher in post-bilateral nephrectomy patients when compared with those of control subjects (101.1 ± 65.5 vs. 19.6 ± 5.0; p < 0.01). Additionally, renalase concentrations, calculated per gram of hemoglobin, were significantly higher in patients after bilateral nephrectomy in comparison with those of healthy subjects (994.9 ± 345.5 vs. 697.6 ± 273.4, p = 0.015). There were no statistically significant differences in plasma concentrations of noradrenaline or adrenaline. In contrast, the concentration of dopamine was significantly lower in post-nephrectomy patients when compared with those of healthy subjects (116.8 ± 147.7 vs. 440.9 ± 343.2, p < 0.01). Conclusions: Increased serum levels of renalase in post-bilateral nephrectomy hemodialysis patients are likely related to production in extra-renal organs as a result of changes in the cardiovascular system and hypertension.


2006 ◽  
Vol 84 (1) ◽  
pp. 252-262 ◽  
Author(s):  
Patricia Castilla ◽  
Rocío Echarri ◽  
Alberto Dávalos ◽  
Francisca Cerrato ◽  
Henar Ortega ◽  
...  

2002 ◽  
Vol 58 (09) ◽  
pp. 205-210 ◽  
Author(s):  
K. Dewitte ◽  
A. Dhondt ◽  
N. Lameire ◽  
D. Stöckl ◽  
L.M. Thienpont

1981 ◽  
Vol 98 (3) ◽  
pp. 407-412 ◽  
Author(s):  
Arne Nygren ◽  
Lars Erik Lindblad ◽  
Lars Sundblad

Abstract. In six healthy subjects fasted overnight two different experiments were carried out on separate days and in random order: A. Oral glucose followed 60 min later by iv glipizide. B. Iv glipizide followed 60 min later by oral glucose. Each experiment was divided into two 60 min periods, and the fractionated insulin uptake by forearm tissue was calculated for each 60 min period. When the fractional insulin uptake values for these four 60 min periods were compared it was found that the uptake of insulin was significantly higher for the 60 min period that was obtained in response to glucose without glipizide pre-treatment, than it was for any of the other 60 min periods. Moreover, in some of the participants the venous insulin concentration occasionally exceeded the corresponding arterial insulin concentration after iv glipizide administration. These findings imply that glipizide may decrease insulin binding to peripheral insulin receptors in healthy individuals.


Author(s):  
Björn Anderstam ◽  
Ann-Christin Bragfors-Helin ◽  
Jonas Axelsson ◽  
Abdul R. Qureshi ◽  
Rolf Wibom ◽  
...  

1997 ◽  
Vol 43 (7) ◽  
pp. 1188-1195 ◽  
Author(s):  
Koji Takada ◽  
Hidekazu Nasu ◽  
Nozomu Hibi ◽  
Yutaka Tsukada ◽  
Toshiaki Shibasaki ◽  
...  

Abstract Ubiquitin, which can conjugate with cellular proteins, is classified into two forms: free ubiquitin and multiubiquitin chains. The latter is active as a signal for degradation of the targeted proteins. We found both forms in human serum and, using two immunoassays, quantitated them in sera from healthy subjects and patients with some diseases. Because of putative leakage of erythrocyte ubiquitin, hemolytic serum and serum obtained after long incubation (&gt;1–2 h) of blood at room temperature were excluded. Serum concentrations of multiubiquitin chains and free ubiquitin were substantially higher in rheumatoid arthritis and hemodialysis patients, respectively, than healthy subjects. Additionally, in acute viral hepatitis, serum multiubiquitin chain concentrations were increased in the acute phase, decreased in the recovery phase, and correlated with alanine and aspartate aminotransferase activities (r = 0.676 and 0.610, P &lt;0.0001 and &lt;0.001, respectively). Therefore, serum ubiquitin may have prognostic value.


Circulation ◽  
1997 ◽  
Vol 95 (9) ◽  
pp. 2271-2276 ◽  
Author(s):  
G. Ligtenberg ◽  
P. J. Blankestijn ◽  
P. L. Oey ◽  
G. H. Wieneke ◽  
A. C. van Huffelen ◽  
...  

2009 ◽  
Vol 19 (4) ◽  
pp. 283-290 ◽  
Author(s):  
Maria Skouroliakou ◽  
Maria Stathopoulou ◽  
Aikaterini Koulouri ◽  
Ifigenia Giannopoulou ◽  
Dimitrios Stamatiades ◽  
...  

Nephron ◽  
2021 ◽  
pp. 1-5
Author(s):  
Christof Ulrich ◽  
Bogusz Trojanowicz ◽  
Roman Fiedler ◽  
Frank Bernhard Kraus ◽  
Gabriele I. Stangl ◽  
...  

<b><i>Introduction:</i></b> Low serum testosterone is related to increased mortality in male dialysis patients. An association of vitamin D status with serum androgen levels with concordant seasonal variation has been described, but it is undecided whether vitamin D supplementation improves testosterone levels. <b><i>Methods:</i></b> In a randomized, placebo-controlled, and double-blind manner, we investigated the effects of an oral vitamin D supplementation in healthy subjects and hemodialysis patients on testosterone levels. One hundred three healthy individuals received cholecalciferol 800 IE/day (<i>n</i> = 52) or placebo (<i>n</i> = 51) for 12 weeks. Thirty-three hemodialysis patients received cholecalciferol adapted to their serum levels following current guidelines (<i>n</i> = 15) or placebo (<i>n</i> = 18) for 12 weeks. <b><i>Results:</i></b> In healthy individuals, 25(OH)D3 levels rose significantly in the verum group (38.1 ± 13.7 vs. 72.5 ± 15.4 nmol/L, <i>p</i> &#x3c; 0.001), whereas in the placebo group, levels dropped (37.7 ± 14.7 vs. 31.9 ± 13.1, <i>p</i> &#x3c; 0.001). Testosterone levels did not change significantly (verum, males: 20.9 ± 6.6 vs. 20.5 ± 7.9 nmol/L, <i>p</i> = 0.6; verum, females: 0.9 ± 0.5 vs. 0.92 ± 0.5, <i>p</i> = 0.4; placebo, males: 18.5 ± 10.2 vs. 21.8 ± 16.5, <i>p</i> = 0.07, placebo, females: 1.6 ± 4.2 vs. 1.6 ± 4.9, <i>p</i> = 0.6). In dialysis patients, the mean cholecalciferol level was only 32.3 ± 17.8 nmol/L, with only 2% of the values being within the normal range. Cholecalciferol levels normalized in the verum group (29.4 ± 11.2 vs. 87.8 ± 22.3, <i>p</i> &#x3c; 0.001), whereas levels dropped further in the placebo group (33.6 ± 16.6 vs. 24.6 ± 8.0 nmol/L, <i>p</i> &#x3c; 0.001). Testosterone levels did not change significantly (verum, males: 8.0 ± 3.7 vs. 7.8 ± 3.8, <i>p</i> = 0.8; verum, females: 1.3 ± 1.0 vs. 1.2 ± 1.0 nmol/L, <i>p</i> = 0.5; placebo, males: 11.9 ± 5.0 vs. 11.6 ± 4.0 nmol/L, <i>p</i> = 0.6; placebo, females: 0.8 ± 0.5 vs. 0.7 ± 0.4 nmol/L, <i>p</i> = 0.8). <b><i>Conclusion:</i></b> Serum testosterone levels in hemodialysis patients and healthy individuals are independent from vitamin D status and cannot be significantly increased by cholecalciferol supplementation.


Sign in / Sign up

Export Citation Format

Share Document